All together these findings support that Venetoclax + Nilotinib combined treatment eliminates the committed CML cells, while the more primitive cells were less sensitive to BCL2 and BCR-ABL1 kinase inhibition. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.